Intralipid therapy for recurrent implantation failure: new hope or false dawn?

Evidence-based management of recurrent miscarriages

“…[119] Evidence does not support routine use of intralipid therapy. [120] The Cochrane review analyzed various strategies including paternal cell immunization, third-party donor leukocytes, trophoblast membranes, and intravenous immune globulin. None of these interventions proved beneficial over placebo in improving the live birth rate.…”

“…Well controlled, large-scale, and confirmatory studies required before it can be recommended for routine use[118120] (Evidence level III)…”

Intralipid Infusion is the Current Favorite of Gynecologists for Immunotherapy

“…However, there is insufficient current evidence of acceptable quality to permit an assumption that intralipid therapy is an effective treatment for women undergoing repeated implantation failures. Shreeve and Sadek [19] in their elegant review have concluded that appropriately controlled, large-scale, confirmatory studies are necessary to prove the efficacy of intralipid before it can be recommended for routine use.…”

Miscarriage Definitions, Causes and Management: Review of Literature

“…Evidence does not support the use of intralipid in RM [76] . A Cochrane systematic review has shown that the use of various forms of immunotherapy in women with unexplained RM provides no significant beneficial effect over placebo in preventing further miscarriage [21] .…”